Oncopeptides AB (publ) (0RN4.L)

Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa

DUBAI, United Arab Emirates and STOCKHOLM, Sweden, March 27, 2024 (GLOBE NEWSWIRE) -- Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”) countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq. Under the terms of this e